Lincoln Pharmaceuticals Limited

Pharmaceuticals: Major/ NSE

Compiled

Auto-generated from filings and public channels — no analyst dossier.

If management delivers what it guided

arithmetic on filed guidance and past valuations · not a price target

LINCOLN

FY26 → FY28 · 2 years of guidance · ~1.7 years from today₹577 today

BEAR

₹498

-14%-8% a yr

12.8% a year · 8.9x exit

BASE

₹827

+43%+24% a yr

22.2% a year · 12.6x exit

BULL

₹1,004

+74%+40% a yr

30.1% a year · 13.5x exit

Where the market has priced it

5x13x today17x

this company's own median multiple sits 58% below its filed-industry peers; the scenario uses its own

How these numbers are produced

Earnings base	FY26 fiscal year EPS ₹43.88 (screener)
Guided growth	22.2% a year, said on the call of 23-Feb-2026 · transcript
Read across as	stated FY28 revenue target of Rs 1000.0 crore, read as flat-margin earnings growth — medium confidence
Delivery calibration	0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings
Exit multiple	8.91x / 12.63x / 13.51x, this company’s own p20 / median / p80 across 10 filed years
Filed-industry peers	median 30.27x across 38 peers — the cross-check, not the input
Arithmetic	base EPS × (1 + guided growth × delivery)² × exit multiple

Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.

How to read this

It answers one question. If this management delivers the growth it told its own investors it would, and the market pays what it has historically paid for this company's earnings, where does the arithmetic land? Nothing here is a forecast of the share price.
Three cases, two moving parts. Bear, base and bull vary the delivery — what fraction of guidance managements actually file — and the exit multiple together, because a company that misses its guidance is usually de-rated for missing it. Each case shows the growth rate and the multiple that produced it.
Read the width, not just the middle. A wide gap between bear and bull means the inputs are uncertain, not that the upside is bigger. A narrow range is a more confident statement than a high one.
“Where the market has priced it” puts today's P/E on the company's own historical range. Sitting far below that range is why a scenario can look enormous: the number is then mostly about re-rating, not about delivery, and the board marks those separately.
The bullets underneath are the caveats — a borrowed peer multiple, a thin filed history, an earnings base that carried a one-off. They are the reasons to trust the number less, listed rather than buried.

Not a price target, not a recommendation, and not a forecast of what the stock will do. The field guide covers the method.

What management said

from NSE earnings-call filings · extracted, not interpreted

implied earnings growth 22%

Call 23-Feb-2026 · bridge confidence medium · transcript PDF

Coverage

SectorPharmaceuticals: Major

Dossiersnone

Guidanceyes

Scenarioyes

Street chatter

unverified · logged from public channels

⚠️ Pharmaceuticals & Biotechnology (1 stocks, -11.1%)

Weak Results (LINCOLN)

⚠️ Leisure Services (1 stocks, -13.9%)

Delta Corp: Favorable Supreme Court order expected on GST.

Regulatory29 May 05:31

📢 LICI -49.7% - Strong Growth, Margi

📢 DELTACORP -14.9% - GST Order Expected

📊 LINCOLN -9.3% - Weak Results

📢 BESTAGRO -8.8% - Q4 Audio Recording

29 May 03:39

Lincoln Pharma: FY26 Net Profit Increases, Dividend Declared, Future Growth Planned #LINCOLN - 20 minutes ago

Capital action28 May 12:00